Last reviewed · How we verify
Sichuan Huiyu Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Ferric Carboxymaltose Injection [Injectafer®] | Ferric Carboxymaltose Injection [Injectafer®] | marketed | ||||
| Ferric Carboxymaltose Injection | Ferric Carboxymaltose Injection | marketed | Iron replacement agent | Iron metabolism pathway; transferrin receptor | Hematology |
Therapeutic area mix
- Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
- Ain Shams University · 1 shared drug class
- American Regent, Inc. · 1 shared drug class
- Azad Pharma AG · 1 shared drug class
- CN NGANOU-GNINDJIO, MD, MSc · 1 shared drug class
- China-Japan Friendship Hospital · 1 shared drug class
- Hallym University Medical Center · 1 shared drug class
- J. Uriach and Company · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sichuan Huiyu Pharmaceutical Co., Ltd:
- Sichuan Huiyu Pharmaceutical Co., Ltd pipeline updates — RSS
- Sichuan Huiyu Pharmaceutical Co., Ltd pipeline updates — Atom
- Sichuan Huiyu Pharmaceutical Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sichuan Huiyu Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sichuan-huiyu-pharmaceutical-co-ltd. Accessed 2026-05-18.